Kết quả bước đầu hóa xạ trị tiền phẫu bằng kỹ thuật xạ trị điều biến liều trên bệnh nhân ung thư thực quản 1/3 giữa - dưới=The initial results of neoadjuvant concurrent chemoradiotherapy using intensity modulated radiation therapy technique in stage II-III middle-lower third esophageal cancer

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Phương Thảo Cao, Thị Trang Lê, Đình Châu Nguyễn, Quỳnh Tú Nguyễn, Thị Hà Nguyễn, Thị Phương Thảo Nguyễn, Thị Mai Trịnh

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y dược lâm sàng 108, 2024

Mô tả vật lý: tr.47-54

Bộ sưu tập: Metadata

ID: 244874

Thêm vào giỏ

Đánh giá kết quả bước đầu hóa xạ trị tiền phẫu sử dụng kỹ thuật xạ trị điều biến liều theo sau là phẫu thuật trên bệnh nhân ung thư thực quản 1/3 giữa-dưới tại Bệnh viện Trung ương Quân đội 108. Đối tượng và phương pháp: Nghiên cứu mô tả hồi cứu trên 83 bệnh nhân ung thư thực quản vị trí 1/3 giữa, dưới giai đoạn II, III từ 1/2027 đến 11/2023 được tiến hành hóa xạ trị 41,4Gy/23 phân liều kết hợp hóa chất paclitaxel/carboplatin hàng tuần và phẫu thuật sau 6-8 tuần. Kết quả: Tuổi trung bình là 57 tuổi, 91,6% có triệu chứng nuốt nghẹn, giai đoạn bệnh chủ yếu giai đoạn III với tỷ lệ 80,7%
Tỷ lệ đáp ứng hoàn toàn trên giải phẫu bệnh là 37,3% (pT0N0). Các tác dụng không mong muốn chủ yếu độ 1-2 bao gồm hạ bạch cầu, viêm niêm mạc thực quản. Kết luận: Hóa xạ trị tiền phẫu sử dụng kỹ thuật điều biến liều là phương pháp điều trị có hiệu quả cho bệnh nhân ung thư thực quản 1/3 giữa-dưới giai đoạn II-III với tác dụng không mong muốn có thể chấp nhận được.To assess the intial treatment results of neoadjuvant chemoradiation using intensity modulated radiation therapy (IMRT) technique followed by surgery in the middle and lower thirds, stage II-III esophageal cancer patients at the 108 Military Central Hospital. Subject and method: A retrospective study on 83 patients with middle and lower, stage II-III esophageal cancer who received 41.4Gy in 23 fractions concurrent chemoradiation with weekly paclitaxel/carboplatin and followed by surgery. Result: The average age was 57 years old. The most common symptom was dysphagia with 91.6% patients and there were 80.7% patients in stage III (AJJC8). The pathology complete response was 37.3% (pT0N0). Adverse effects including fatigue, esophageal mucositis, and leukopenia, most of which were in grade 1-2. Conclusion: Preoperative chemoradiation using IMRT is an effective treatment method for stgage II-III esophageal cancer patients with acceptable side effects.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR